LINC02083: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02083

NCBI ID: G107986147

LINC02083

Other Name(s): Long intergenic non-protein coding RNA 2083 | long intergenic non-protein coding RNA 2083

LINC02083: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02083 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in various tissues and organs, including brain, heart, and liver. LINC02083 has been shown to play a role in the regulation of gene expression and has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related Characteristics

LINC02083 has been associated with a number of diseases due to its involvement in the regulation of gene expression. One of the most well-studied associations is its role in cancer. LINC02083 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in the regulation of cell survival and proliferation, which are key factors in the development and progression of cancer.

In addition to its association with cancer, LINC02083 has also been linked to a number of other diseases, including neurodegenerative diseases and autoimmune disorders. For example, LINC02083 has been shown to be involved in the regulation of neurotransmitter synthesis and release in the brain, which is implicated in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's. It has also been associated with the regulation of immune cell function, which is implicated in the development of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

Drug Intervention Strategies

Due to its involvement in a number of diseases, LINC02083 has become an attractive target for drug intervention. One approach to targeting LINC02083 is to use small molecules or antibodies to inhibit its expression or activity. This can be done by targeting the RNA molecule itself, or by targeting proteins that interact with the RNA molecule.

Another approach to targeting LINC02083 is to use drugs that modulate its stability or activity. For example, drugs that inhibit RNA binding proteins or that increase the degradation of RNA molecules could potentially reduce the levels of LINC02083 in the body and interfere with its function.

Biomarker Properties

In addition to its association with diseases, LINC02083 has also been shown to be a potential biomarker for a number of diseases. For example, LINC02083 has been shown to be a potential biomarker for cancer, as its levels are often elevated in cancer samples compared to non-cancer samples. It has also been shown to be a potential biomarker for neurodegenerative diseases, as its levels are often elevated in brain samples from patients with neurodegenerative diseases.

Conclusion

LINC02083 is a long intergenic non-protein-coding RNA that has been associated with a number of diseases. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of LINC02083 in disease and to develop effective drugs that can target it.

Protein Name: Long Intergenic Non-protein Coding RNA 2083

The "LINC02083 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02083 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets